ストックスクリーナーアプリを入手
11.55
1.49%
0.17
前日終値:
$11.38
開ける：
$11.58
24時間の取引高:
4.36M
Relative Volume:
0.71
時価総額：
$7.85B
収益：
$125.68M
当期純損益:
$4.81B
株価収益率:
2.0442
EPS:
5.65
ネットキャッシュフロー:
$-781.21M
1週間 パフォーマンス:
+0.96%
1か月 パフォーマンス:
+1.32%
6か月 パフォーマンス:
+3.40%
1年 パフォーマンス:
+7.54%
1日の値動き範囲:
$11.35
$11.64
1週間の範囲:
$11.31
$11.64
52週間の値動き範囲:
$8.73
$13.05
Roivant Sciences Ltd Stock (ROIV) Company Profile
ROIV を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
11.55 | 7.74B | 125.68M | 4.81B | -781.21M | 5.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-10 | 再開されました | Goldman | Buy |
| 2024-02-15 | 開始されました | Wolfe Research | Outperform |
| 2024-01-05 | 開始されました | Piper Sandler | Overweight |
| 2023-12-12 | 開始されました | Deutsche Bank | Buy |
| 2023-10-17 | 開始されました | Guggenheim | Buy |
| 2023-06-08 | 開始されました | BofA Securities | Neutral |
| 2022-10-27 | 開始されました | JP Morgan | Overweight |
| 2022-05-23 | 開始されました | SVB Leerink | Outperform |
| 2022-04-29 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-12-15 | 開始されました | Goldman | Buy |
| 2021-11-08 | 開始されました | H.C. Wainwright | Buy |
| 2021-10-28 | 開始されました | Citigroup | Buy |
| 2021-10-26 | 開始されました | Cowen | Outperform |
| 2021-10-26 | 開始されました | Jefferies | Buy |
| 2021-10-26 | 開始されました | Truist | Buy |
すべてを表示
Roivant Sciences Ltd (ROIV) 最新ニュース
Is Roivant Sciences Ltd. a good long term investmentUnbelievable profit margins - Autocar Professional
Roivant Sciences (ROIV) Anticipated to Benefit from Brepocitinib Developments | ROIV Stock News - GuruFocus
Goldman Sachs Resumes Roivant Sciences (ROIV) Coverage with ‘Buy’ Rating - MSN
Vivek Ramaswamy to welcome third child soon: Meet his wife and his two elder sons - Times of India
Roivant Sciences Ltd. Stock Analysis and ForecastFree Stock Market Beginners Guide - Autocar Professional
Roivant Sciences’ president Venker sells $1.15 million in shares By Investing.com - Investing.com South Africa
Roivant Sciences’ president Venker sells $1.15 million in shares - Investing.com Australia
Roivant Sciences President Eric Venker Sells 100k Shares at $11.52, Buys 100k at $3.85. - AInvest
10 Best Biotech Stocks to Buy According to Billionaire Steve Cohen - Insider Monkey
What drives Roivant Sciences Ltd. stock priceExceptional risk-adjusted gains - jammulinksnews.com
What analysts say about Roivant Sciences Ltd. stockTriple-digit profit margins - jammulinksnews.com
(ROIV) Investment Analysis and Advice - news.stocktradersdaily.com
Goldman Sachs resumes Roivant Sciences stock coverage with Buy rating By Investing.com - Investing.com South Africa
Goldman Sachs resumes Roivant Sciences stock coverage with Buy rating - Investing.com India
How to Take Advantage of moves in (ROIV) - news.stocktradersdaily.com
Roivant Sciences: Booming Pipeline Without Product Revenues Creates Valuation Riddle - Seeking Alpha
'Just the beginning': Vivek Ramaswamy breaks record in raising fund for Guv election campaign, $8.5 milli - Times of India
Hedge Fund and Insider Trading News: Ken Griffin, Warren Buffett, Michael Burry, AQR Capital Management, Tiger Global Management, Amplify Energy Corp (AMPY), Roivant Sciences ltd (ROIV), and More - Insider Monkey
Roivant Sciences Subsidiary Pulmovant Publishes Positive Phase 1 Data for Inhaled PH Treatment Mosliciguat - Yahoo Finance
Roivant Sciences (ROIV): Ramaswamy sells $13 million in shares - Investing.com
HC Wainwright & Co. Reiterates Buy Rating for Roivant Sciences (ROIV) | ROIV Stock News - GuruFocus
Cantor Fitzgerald reiterates overweight rating on Roivant Sciences stock By Investing.com - Investing.com India
H.C. Wainwright reiterates buy rating on Roivant Sciences stock By Investing.com - Investing.com India
Guggenheim maintains buy rating on Roivant Sciences stock amid DM study - Investing.com India
JPMorgan Maintains Positive Outlook on Roivant Sciences (ROIV) | ROIV Stock News - GuruFocus
Roivant (ROIV) Hosts Investor Webinar on Brepocitinib's Role in Dermatomyositis | ROIV Stock News - GuruFocus
Long Term Trading Analysis for (ROIV) - news.stocktradersdaily.com
Roivant (ROIV) Publishes Promising Phase 1 Results for Inhaled M - GuruFocus
Roivant Sciences at Goldman Sachs Conference: Strategic Execution Focus By Investing.com - Investing.com South Africa
Roivant Sciences at Goldman Sachs Conference: Strategic Execution Focus - Investing.com Australia
Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis - Yahoo Finance
Rare Disease Breakthrough: Roivant Reveals Brepocitinib Data for Dermatomyositis Treatment - Stock Titan
Major Shareholder Cashes Out Millions in Roivant Sciences Stock - TipRanks
(ROIV) Trading Advice - news.stocktradersdaily.com
Vivek Ramaswamy’s firm wants to buy biotech companies to bet on bitcoin - MSN
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $324,000 Stock Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) - Defense World
Roivant Sciences Earnings Call: Balancing Growth and Challenges - MSN
Roivant outlines packed 36-month launch and data cycle with under $5B cash reserve and multi-blockbuster pipeline - MSN
Decoding Roivant Sciences Ltd (ROIV): A Strategic SWOT Insight - GuruFocus
Roivant Sciences Ltd. (NASDAQ:ROIV) Q4 2024 Earnings Call Transcript - Insider Monkey
Roivant Sciences Full Year 2025 Earnings: EPS Beats Expectations, Revenues Lag - simplywall.st
While Wall Street Naps, These 10 Stocks Run Wild - Insider Monkey
Why Roivant Sciences Ltd. (ROIV) Surged On Thursday - Insider Monkey
Roivant Sciences Ltd (ROIV) 財務データ
収益
当期純利益
現金流量
EPS
Roivant Sciences Ltd (ROIV) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Venker Eric | President & Immunovant CEO |
Jul 21 '25 |
Sale |
11.52 |
100,000 |
1,152,000 |
1,462,223 |
0.97%
0.22%
大文字化:
|
ボリューム (24 時間):